| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-09-17 | Jardiance® (empagliflozin) | type 2 diabetes | 3 | Boehringer Ingelheim (Germany) Eli Lilly (USA - IN) | Cardiovascular diseases - Metabolic diseases |
| 2015-09-16 | Strensiq™ (asfotase alfa) | hypophosphatasia | Alexion Pharmaceuticals (USA - CT) | Rare diseases - Genetic diseases - Metabolic diseases | |
| 2015-09-15 | ZP-I-98 | type 2 diabetes | preclinical | Zealand Pharma (Denmark) | Metabolic diseases |
| 2015-09-15 | diagnostic method used to identify NASH patients that should be treated with elafibranor (GFT505) | NASH (non-alcoholic steatohepatitis) | Genfit (France) | Liver diseases - Hepatic diseases - Diagnostic | |
| 2015-09-15 | hepatic porphyrias, acute intermittent porphyria (AIP), variegate porphyria, and hereditary coproporphyria, suffering from recurrent attacks | Alnylam Pharmaceuticals (USA - MA) the American Porphyria Consortium (USA) The European Porphyria Network | Genetic diseases - Metabolic diseases - Rare diseases | ||
| 2015-09-14 | autologous bone marrow cells | multiple sclerosis | 1 | North Bristol NHS Trust (UK) | Neurodegenerative diseases |
| 2015-09-13 | marizomib, pomalidomide and dexamethasone | multiple myeloma in relapse, refractory multiple myeloma | 1 | Triphase Accelerator (Canada - USA - CA) Celgene (USA - NJ) | Cancer - Oncology |
| 2015-09-10 | MN-166 (ibudilast) | amyotrophic lateral sclerosis | 2 | Medicinova (USA - CA) | Neurodegenerative diseases - Rare diseases |
| 2015-09-10 | arimoclomol citrate | Niemann-Pick disease type C | 2-3 | Orphazyme (Denmark) | Rare diseases - Genetic diseases |
| 2015-09-10 | somavaratan (VRS-317) | adult growth hormone deficiency | 2 | Versartis (USA - CA) | Endocrinological diseases - Hormonal diseases |
| 2015-09-10 | DTX101 | hemophilia B | 1-2 | Dimension Therapeutics (USA - MA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2015-09-10 | Resolaris® | facioscapulohumeral muscular dystrophy | 1-2 | Atyr Pharma (USA - CA) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2015-09-09 | Tedopi® (OSE2101) | advanced non-small cell lung cancer | 2 | OSE Pharma (France) now OSE Immunotherapeutics | Cancer - Oncology |
| 2015-09-09 | IFN alpha-Kinoid® (IFN-K) | systemic lupus erythematosus | 1-2 | Neovacs (France) | Autoimmune diseases |
| 2015-09-09 | TG-1101 (ublituximab), TGR-1202 and pembrolizumab | chronic lymphocytic leukemia | 1-2 | TG Therapeutics (USA - NY) | Cancer - Oncology |
| 2015-09-09 | phage therapy | Escherichia coli and Pseudomonas aeruginosa skin infections in burn patients | 1-2 | Ministry of Defence (France) Pherecydes Pharma (France) Clean Cells (France) | Dermatological diseases - Infectious diseases |
| 2015-09-09 | AST-OPC1 (oligodendrocyte progenitor cells) | spinal cord injury | preclinical | Asterias Biotherapeutics (USA - CA) | Rare diseases - Regenerative medicine |
| 2015-09-09 | ZP4207 | treatment of mild to moderate hypoglycemia in diabetes patients | 1 | Zealand Pharma (Denmark) | Metabolic diseases |
| 2015-09-09 | GKT137831 | diabetic nephropathy | 2 | Genkyotex (Switzerland) | Metabolic diseases - Renal diseases - Kidney diseases |
| 2015-09-08 | PRM-151 (recombinant human pentraxin-2) | idiopathic pulmonary fibrosis (IPF) | 2 | Promedior (USA - MA) | Lung diseases - Respiratory diseases - Rare diseases |
